Roman A. Bontsevich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Roman A. Bontsevich has a total of 330 co-authors. Here are the top co-authors by number of shared publications:
- Maksim Leonidovich Maksimov
FSBEI CPE Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, FSAEI HE Pirogov Russian National Research Medical University of the Ministry of Health of Russia
40 shared publications - Galina G. Ketova
South Ural State Medical University
21 shared publications - Olga G. Kompaniets
Kuban State Medical University
18 shared publications - Georgy I. Zavitkevich
Mari State University
15 shared publications - Vera A. Nevzorova
Pacific State Medical University
14 shared publications - Valeriya O. Barysheva
I.I. Dedov National Medical Research Center of Endocrinology of the Ministry of Health of the Russia ; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russia
13 shared publications
Latest Publications
- 30 October 2026
- Published by PANORAMA Publishing House
- No. 5,p. 55-66
Evolution of antimicrobial chemotherapy: new classes and promising directions
This article examines the evolution of antimicrobial chemotherapy in the context of the global rise in antimicrobial resistance. The objective is to systematize current data on new classes of antimicrobial agents and promising avenues for their development. The study analyzes results from clinical and preclinical research conducted between 2020 and 2026, covering modified beta-lactams and beta- lactamase inhibitors (sulbactam-durlobactam, aztreonam-avibactam, cefiderocol, cefepime-zidebactam, cefepime-taniborbactam, and imipenem-funobactam), as well as antimicrobial peptides, endolysins, natural and plant-derived metabolites, therapeutic nucleic acids, synthetic hybrids, and molecules designed using artificial intelligence. Several fundamentally new classes of drugs are described: triazaacenaphthylenes (gepotidacin), DNA polymerase IIIC inhibitors (ibezapolstat), lipopolysaccharide transport inhibitors (zosurabalpin), and abaucin. A paradigm shift in drug development is highlighted, i.e. a transition from modifying existing structures to exploring new targets and molecular classes. It is concluded that AI-accelerated drug design holds great promise for overcoming the resistance crisis.
- 30 October 2026
- Published by PANORAMA Publishing House
- No. 5,p. 55-66
Evolution of antimicrobial chemotherapy: new classes and promising directions
This article examines the evolution of antimicrobial chemotherapy in the context of the global rise in antimicrobial resistance. The objective is to systematize current data on new classes of antimicrobial agents and promising avenues for their development. The study analyzes results from clinical and preclinical research conducted between 2020 and 2026, covering modified beta-lactams and beta- lactamase inhibitors (sulbactam-durlobactam, aztreonam-avibactam, cefiderocol, cefepime-zidebactam, cefepime-taniborbactam, and imipenem-funobactam), as well as antimicrobial peptides, endolysins, natural and plant-derived metabolites, therapeutic nucleic acids, synthetic hybrids, and molecules designed using artificial intelligence. Several fundamentally new classes of drugs are described: triazaacenaphthylenes (gepotidacin), DNA polymerase IIIC inhibitors (ibezapolstat), lipopolysaccharide transport inhibitors (zosurabalpin), and abaucin. A paradigm shift in drug development is highlighted, i.e. a transition from modifying existing structures to exploring new targets and molecular classes. It is concluded that AI-accelerated drug design holds great promise for overcoming the resistance crisis.
- 30 October 2026
- Published by PANORAMA Publishing House
- No. 5,p. 20-31
Unconventional medicine: where the line of safety is drawn
This article examines the safety of unconventional medicines from the perspectives of clinical pharmacology and healthcare organization. It distinguishes between complementary, alternative, and integrative medicine and provides data on the prevalence of these practices globally, in Europe, and in Russia, covering phytotherapy, dietary supplements, homeopathy, manual therapies, and mind-body interventions. Key risks are categorized, including delayed medical consultation, the rejection of evidence-based treatment, drug interactions involving herbal products (such as the interaction between St. John’s wort and warfarin), the hepatotoxicity and nephrotoxicity of plant-based remedies, the contamination and adulteration of dietary supplements, and the tendency for patients to conceal their use of such products from healthcare providers. The presence of methods with an insufficient evidence base in domestic clinical guidelines, as well as the validity of the levels of certainty and strength of evidence assigned to them, was analyzed separately. It is concluded that the critical issue is not the mere use of unconventional methods, but rather their uncontrolled application, without any assessment of their safety or compatibility with prescribed pharmacological therapy.
- 30 October 2026
- Published by PANORAMA Publishing House
- No. 5,p. 20-31
Unconventional medicine: where the line of safety is drawn
This article examines the safety of unconventional medicines from the perspectives of clinical pharmacology and healthcare organization. It distinguishes between complementary, alternative, and integrative medicine and provides data on the prevalence of these practices globally, in Europe, and in Russia, covering phytotherapy, dietary supplements, homeopathy, manual therapies, and mind-body interventions. Key risks are categorized, including delayed medical consultation, the rejection of evidence-based treatment, drug interactions involving herbal products (such as the interaction between St. John’s wort and warfarin), the hepatotoxicity and nephrotoxicity of plant-based remedies, the contamination and adulteration of dietary supplements, and the tendency for patients to conceal their use of such products from healthcare providers. The presence of methods with an insufficient evidence base in domestic clinical guidelines, as well as the validity of the levels of certainty and strength of evidence assigned to them, was analyzed separately. It is concluded that the critical issue is not the mere use of unconventional methods, but rather their uncontrolled application, without any assessment of their safety or compatibility with prescribed pharmacological therapy.
- Open Access
- 18 September 2026
- Published by Far Eastern Scientific Center Of Physiology and Pathology of Respiration in Bulletin physiology and pathology of respiration
- No. 101,p. 8-21
Analysis of medical students' knowledge about bronchial asthma: a multicenter study ASSA-IV
Introduction. The high prevalence of asthma in the general population necessitates the assessment of medical students' theoretical knowledge regarding the pathogenesis, diagnosis, and management of this disease. Aim. To determine the level of basic knowledge among senior medical students across key thematic blocks of asthma. Materials and methods. The fourth stage of the multicenter study "The Assessment of Physicians' (Medical Students') Knowledge in the Field of Bronchial Asthma" (ASSA) was conducted between October 2023 and May 2025 using a validated, author-developed questionnaire based on current national and international clinical guidelines. The questionnaire consistedof 21 questions divided into two blocks: "Etiopathogenesis" and "Pharmacotherapy". Results. A total of 487 correctly completed questionnaires from 5 universities of the Russian Federation were analyzed. The average rate of correct answers (ARC) for the entire questionnaire was 69.9 % (95 % CI 68.5–71.3 %), with a median (Me) of 70.6 % [IQR: 59.5%–82.5 %]. In the "Etiopathogenesis" section, the ARC reached 84.0% (95% CI 82.5–85.4 %), whereas in the "Pharmacotherapy" section it was only 59.3 % (95 % CI 57.6–61.0 %). The maximum ARC values were obtained for questions regarding asthma control levels (96.3 %) and the definition of the term "status asthmaticus" (92.6 %). Conversely, the minimum values were recorded for questions concerning sublingual immunotherapy for house dust mite allergies (16.2 %) and add-on therapy at the 4 th step of treatment (27.7%). Significant inter-center differences were revealed across the entire questionnaire (H (4) = 53.263, p < 0.001, ε2 = 0.102) and its individual sections. When compared with the previous stage (ASSA-III), a statistically significant improvement in the results was observed: the overall ARC increased by 3.9 % (69.9 % vs. 66.0 %, p < 0.001), though the effect size remained weak (r = 0.119; CLES = 0.568). Conclusion. Senior medical students demonstrated a proficient level of knowledge regarding the etiopathogenesis and diagnosis of asthma, whereas their understanding of its pharmacotherapy remains insufficient. The significant inter-center variability in the average rate of correct answers underscores the urgent need to standardize educational methods and strengthen practical training in asthma management and treatment selection.
- 18 September 2026
- Published by Far Eastern Scientific Center Of Physiology and Pathology of Respiration in Bulletin physiology and pathology of respiration
- No. 101,p. 8-21
Open AccessAnalysis of medical students' knowledge about bronchial asthma: a multicenter study ASSA-IV
Introduction. The high prevalence of asthma in the general population necessitates the assessment of medical students' theoretical knowledge regarding the pathogenesis, diagnosis, and management of this disease. Aim. To determine the level of basic knowledge among senior medical students across key thematic blocks of asthma. Materials and methods. The fourth stage of the multicenter study "The Assessment of Physicians' (Medical Students') Knowledge in the Field of Bronchial Asthma" (ASSA) was conducted between October 2023 and May 2025 using a validated, author-developed questionnaire based on current national and international clinical guidelines. The questionnaire consistedof 21 questions divided into two blocks: "Etiopathogenesis" and "Pharmacotherapy". Results. A total of 487 correctly completed questionnaires from 5 universities of the Russian Federation were analyzed. The average rate of correct answers (ARC) for the entire questionnaire was 69.9 % (95 % CI 68.5–71.3 %), with a median (Me) of 70.6 % [IQR: 59.5%–82.5 %]. In the "Etiopathogenesis" section, the ARC reached 84.0% (95% CI 82.5–85.4 %), whereas in the "Pharmacotherapy" section it was only 59.3 % (95 % CI 57.6–61.0 %). The maximum ARC values were obtained for questions regarding asthma control levels (96.3 %) and the definition of the term "status asthmaticus" (92.6 %). Conversely, the minimum values were recorded for questions concerning sublingual immunotherapy for house dust mite allergies (16.2 %) and add-on therapy at the 4 th step of treatment (27.7%). Significant inter-center differences were revealed across the entire questionnaire (H (4) = 53.263, p < 0.001, ε2 = 0.102) and its individual sections. When compared with the previous stage (ASSA-III), a statistically significant improvement in the results was observed: the overall ARC increased by 3.9 % (69.9 % vs. 66.0 %, p < 0.001), though the effect size remained weak (r = 0.119; CLES = 0.568). Conclusion. Senior medical students demonstrated a proficient level of knowledge regarding the etiopathogenesis and diagnosis of asthma, whereas their understanding of its pharmacotherapy remains insufficient. The significant inter-center variability in the average rate of correct answers underscores the urgent need to standardize educational methods and strengthen practical training in asthma management and treatment selection.
- 30 June 2026
- Published by PANORAMA Publishing House
- No. 3,p. 58-65
Analysis of structure and dynamics of the anti-asthma drugs market in the Russian Federation: retail and hospital segments
Anti-asthma drugs occupy an important place in the pharmacotherapy of chronic respiratory diseases, which determines the need for a comprehensive analysis of this segment of the pharmaceutical market. The purpose of this study was to identify quantitative and structural patterns in the development of the retail and hospital segments of the R03 drug market based on recent analytical data. The information base included analytical materials from RNC Pharma and public procurement data for 2025, processed using comparative, structural, and dynamic analysis methods, as well as elements of pharmacoeconomic evaluation. It was found that in 2025 both retail and hospital market segments demonstrated steady growth, accompanied by an increase in consumption volumes and value indicators. Strengthening of domestic manufacturers’ positions was identified, especially in the hospital segment, along with significant price differentiation between domestic and imported drugs. The retail market was characterized by a high level of concentration combined with a wide range of product offerings. Additionally, pronounced seasonality of demand and signs of transformation in consumer behavior were observed in early 2026. The obtained results indicate active import substitution processes and changes in consumption patterns, which require further study in terms of accessibility and effectiveness of pharmacotherapy.
- 30 June 2026
- Published by PANORAMA Publishing House
- No. 3,p. 58-65
Analysis of structure and dynamics of the anti-asthma drugs market in the Russian Federation: retail and hospital segments
Anti-asthma drugs occupy an important place in the pharmacotherapy of chronic respiratory diseases, which determines the need for a comprehensive analysis of this segment of the pharmaceutical market. The purpose of this study was to identify quantitative and structural patterns in the development of the retail and hospital segments of the R03 drug market based on recent analytical data. The information base included analytical materials from RNC Pharma and public procurement data for 2025, processed using comparative, structural, and dynamic analysis methods, as well as elements of pharmacoeconomic evaluation. It was found that in 2025 both retail and hospital market segments demonstrated steady growth, accompanied by an increase in consumption volumes and value indicators. Strengthening of domestic manufacturers’ positions was identified, especially in the hospital segment, along with significant price differentiation between domestic and imported drugs. The retail market was characterized by a high level of concentration combined with a wide range of product offerings. Additionally, pronounced seasonality of demand and signs of transformation in consumer behavior were observed in early 2026. The obtained results indicate active import substitution processes and changes in consumption patterns, which require further study in terms of accessibility and effectiveness of pharmacotherapy.
- 31 March 2026
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 14 (1)
Chronic Obstructive Pulmonary Disease: Economic Burden in Russia and European Countries (Review)
INTRODUCTION. Chronic obstructive pulmonary disease (COPD) is a leading cause of death and significant economic losses for the healthcare system. While there is a trend towards decreasing COPD incidence in Europe, Russia saw the incidence increase by 5%, and the economic burden rose from 0.20% to 0.34% of GDP in 2022–2023. International and nationwide best practices necessitate a further analysis to identify the ways of reducing financial burden on the Russian healthcare system. AIM. This study aimed to identify and evaluate feasibility for the most effective ways to reduce the financial burden when managing COPD patients in the Russian Federation. DISCUSSION. Key differences in COPD epidemiology and cost structure were identified between Russia and EU countries. In the European Union (2001–2019), COPD incidence decreased among men (–9.7%) and increased among women (+4.3%) due to higher smoking rates. In Russia, the incidence continued to grow (+5%), while the mortality remained high (26% of the total death causes). In the EU, main direct costs were attributed to inpatient care (35–64%) and drug therapy (~25%), while the share of indirect costs reached 61–83%. Russian cost structure differed: the share of indirect costs was 92.6%, while among the direct costs, 76.1% was attributed to medicines supply, and only 18.7% covered inpatient care. Effective burden reduction included: smoking cessation (reduced exacerbation risk by 39.7%; hazard ratio 0.65 for abstinence >10 years); prophylactic vaccinations (reduced hospitalizations by 50%, while vaccine refusal increased mortality 162-fold); modern pharmacotherapy (triple therapy: long-acting anticholinergic agents + long-acting beta2-agonists + inhaled glucocorticoids, reduced exacerbation frequency by 24% and mortality by 49%), and pulmonary rehabilitation (OR for hospital readmissions 0.44) still presented poorly in Russia (~10%). CONCLUSIONS. To reduce COPD economic burden in the Russian Federation, it is necessary to increase the coverage with preventive measures (tobacco control programs, immunization), develop pulmonary rehabilitation programs using digital technologies, implement modern pharmacotherapy regimens, and improve physicians’ expertise via continuing medical education.
- 31 March 2026
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 14 (1)
Chronic Obstructive Pulmonary Disease: Economic Burden in Russia and European Countries (Review)
INTRODUCTION. Chronic obstructive pulmonary disease (COPD) is a leading cause of death and significant economic losses for the healthcare system. While there is a trend towards decreasing COPD incidence in Europe, Russia saw the incidence increase by 5%, and the economic burden rose from 0.20% to 0.34% of GDP in 2022–2023. International and nationwide best practices necessitate a further analysis to identify the ways of reducing financial burden on the Russian healthcare system. AIM. This study aimed to identify and evaluate feasibility for the most effective ways to reduce the financial burden when managing COPD patients in the Russian Federation. DISCUSSION. Key differences in COPD epidemiology and cost structure were identified between Russia and EU countries. In the European Union (2001–2019), COPD incidence decreased among men (–9.7%) and increased among women (+4.3%) due to higher smoking rates. In Russia, the incidence continued to grow (+5%), while the mortality remained high (26% of the total death causes). In the EU, main direct costs were attributed to inpatient care (35–64%) and drug therapy (~25%), while the share of indirect costs reached 61–83%. Russian cost structure differed: the share of indirect costs was 92.6%, while among the direct costs, 76.1% was attributed to medicines supply, and only 18.7% covered inpatient care. Effective burden reduction included: smoking cessation (reduced exacerbation risk by 39.7%; hazard ratio 0.65 for abstinence >10 years); prophylactic vaccinations (reduced hospitalizations by 50%, while vaccine refusal increased mortality 162-fold); modern pharmacotherapy (triple therapy: long-acting anticholinergic agents + long-acting beta2-agonists + inhaled glucocorticoids, reduced exacerbation frequency by 24% and mortality by 49%), and pulmonary rehabilitation (OR for hospital readmissions 0.44) still presented poorly in Russia (~10%). CONCLUSIONS. To reduce COPD economic burden in the Russian Federation, it is necessary to increase the coverage with preventive measures (tobacco control programs, immunization), develop pulmonary rehabilitation programs using digital technologies, implement modern pharmacotherapy regimens, and improve physicians’ expertise via continuing medical education.
- Open Access
- 17 March 2026
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 12 (1) , 95-100
The C3435T genetic polymorphism of the ABCB1 (MDR1) gene as a predictor of antihypertensive efficacy of losartan monotherapy in newly diagnosed arterial hypertension
Introduction: Losartan, a selective angiotensin II receptor type 1 antagonist, is transported across cell membrane mediated by P-glycoprotein, the product of the ABCB1 (also known as MDR1) gene. The level of expression of this transporter protein is characterized by significant individual variability, caused by genetic factors. Well-known polymorphisms C3435T and C1236T in the ABCB1 gene potentially could affect a functional activity of the P-glycoprotein, thus modulating the pharmacokinetic parameters and clinical efficacy of the substrates of this transporter, including losartan. Therefore, the aim of this research is to indicate the correlation between common SNPs C3435T and C1236T of the MDR1 gene and the efficacy of 6-week losartan monotherapy course in patients with a newly diagnosed arterial hypertension (AH). Materials and Methods: The study included 34 patients (70.6% women, mean age 48.3 ± 7.4 years). All participants were given losartan 100 mg/day for 6 weeks. Genotyping for C3435T and C1236T polymorphisms was made by using allele-specific PCR with electrophoretic detection. The efficacy of the therapy was evaluated by the reduction of systolic (SBP) and diastolic (DBP) blood pressure from the reference level. Results: Patients with CT or TT genotypes for the C3435T polymorphism showed a statistically meaningful, greater reduction in SBP (11.8% ± 9.7) compared to homozygous CC genotype (”wild” type; 6.7% ± 9.6; p=0.03). No significant differences were found in SBP reduction for the C1236T polymorphism (p=0.07). Changes in DBP did not correlate with either of the studied polymorphisms. Conclusions: The C3435T genetic polymorphism of the MDR1 gene is a potential predictor of the efficacy of losartan antihypertensive therapy. The carriers of the T allele (CT/TT genotypes) demonstrate more expressed hypotensive response, which may be caused by modulation of tissue distribution of the drug or its interaction with endogenous systems (ouabain) regulating blood pressure. The obtained data highlights the importance of a pharmacogenetic approach for personalizing AH treatment.
- 17 March 2026
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 12 (1) , 95-100
Open AccessThe C3435T genetic polymorphism of the ABCB1 (MDR1) gene as a predictor of antihypertensive efficacy of losartan monotherapy in newly diagnosed arterial hypertension
Introduction: Losartan, a selective angiotensin II receptor type 1 antagonist, is transported across cell membrane mediated by P-glycoprotein, the product of the ABCB1 (also known as MDR1) gene. The level of expression of this transporter protein is characterized by significant individual variability, caused by genetic factors. Well-known polymorphisms C3435T and C1236T in the ABCB1 gene potentially could affect a functional activity of the P-glycoprotein, thus modulating the pharmacokinetic parameters and clinical efficacy of the substrates of this transporter, including losartan. Therefore, the aim of this research is to indicate the correlation between common SNPs C3435T and C1236T of the MDR1 gene and the efficacy of 6-week losartan monotherapy course in patients with a newly diagnosed arterial hypertension (AH). Materials and Methods: The study included 34 patients (70.6% women, mean age 48.3 ± 7.4 years). All participants were given losartan 100 mg/day for 6 weeks. Genotyping for C3435T and C1236T polymorphisms was made by using allele-specific PCR with electrophoretic detection. The efficacy of the therapy was evaluated by the reduction of systolic (SBP) and diastolic (DBP) blood pressure from the reference level. Results: Patients with CT or TT genotypes for the C3435T polymorphism showed a statistically meaningful, greater reduction in SBP (11.8% ± 9.7) compared to homozygous CC genotype (”wild” type; 6.7% ± 9.6; p=0.03). No significant differences were found in SBP reduction for the C1236T polymorphism (p=0.07). Changes in DBP did not correlate with either of the studied polymorphisms. Conclusions: The C3435T genetic polymorphism of the MDR1 gene is a potential predictor of the efficacy of losartan antihypertensive therapy. The carriers of the T allele (CT/TT genotypes) demonstrate more expressed hypotensive response, which may be caused by modulation of tissue distribution of the drug or its interaction with endogenous systems (ouabain) regulating blood pressure. The obtained data highlights the importance of a pharmacogenetic approach for personalizing AH treatment.
- 5 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (2) , 56-62
Analysis of risk factors for cardiovascular diseases in patients with type 1 diabetes mellitus
Objective. To analyze features of socio-demographic, behavioral and biological risk factors of cardiovascular diseases development in individuals with type 1 diabetes mellitus. Material and methods. A cross sectional multi enter study included 453 patients — men and women with verified type 1 diabetes mellitus (DM) aged 35—65 years from 14 cities of the Russian Federation. Patients enrolment took place from June 2024 to February 2025. A total of 427 patients (238 males and 189 females) completed the study. The patients’ examination included a physician checkup, completion of questionnaire adapted in National Medical Research Center for Therapy and Preventive Medicine, instrumental studies (measurement of blood pressure, resting heart rate, anthropometric parameters, including body mass index calculation and waist circumference measurement, resting electrocardiography) and evaluation of biochemical parameters of the blood including lipid profile indicators. Results. Mean age of men was 42.6±10.3 years, of women — 40.9 ±10.5 years (p>0.05). The mean age at diagnosis establishment was 27.2±10.3 years for men and 22.4±11.1 years for women (p>0.05). Every second patient, regardless of gender identity, has a nutritional disorder including disorder of dietary salt consumption, fat and refined carbohydrates intake. Despite the young age of patients, every third one has a sedentary lifestyle. Hypercholesterolemia was found in 65.1% of men and 60.8% of women (p>0.05), arterial hypertension in 28.6% of men and 37.6% of women (p>0.05), abdominal obesity in 23.9% of men and 33.9% of women (p=0.03). According to the survey results, 46.2% of men and 61.4% of women experience moderate to high levels of chronic stress (p=0.002). Conclusion. The control of the main behavioral and biological risk factors of cardiovascular diseases development together with effective glycemic control are required to manage cardiovascular risk in persons with type 1 diabetes mellitus.
- 5 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (2) , 56-62
Analysis of risk factors for cardiovascular diseases in patients with type 1 diabetes mellitus
Objective. To analyze features of socio-demographic, behavioral and biological risk factors of cardiovascular diseases development in individuals with type 1 diabetes mellitus. Material and methods. A cross sectional multi enter study included 453 patients — men and women with verified type 1 diabetes mellitus (DM) aged 35—65 years from 14 cities of the Russian Federation. Patients enrolment took place from June 2024 to February 2025. A total of 427 patients (238 males and 189 females) completed the study. The patients’ examination included a physician checkup, completion of questionnaire adapted in National Medical Research Center for Therapy and Preventive Medicine, instrumental studies (measurement of blood pressure, resting heart rate, anthropometric parameters, including body mass index calculation and waist circumference measurement, resting electrocardiography) and evaluation of biochemical parameters of the blood including lipid profile indicators. Results. Mean age of men was 42.6±10.3 years, of women — 40.9 ±10.5 years (p>0.05). The mean age at diagnosis establishment was 27.2±10.3 years for men and 22.4±11.1 years for women (p>0.05). Every second patient, regardless of gender identity, has a nutritional disorder including disorder of dietary salt consumption, fat and refined carbohydrates intake. Despite the young age of patients, every third one has a sedentary lifestyle. Hypercholesterolemia was found in 65.1% of men and 60.8% of women (p>0.05), arterial hypertension in 28.6% of men and 37.6% of women (p>0.05), abdominal obesity in 23.9% of men and 33.9% of women (p=0.03). According to the survey results, 46.2% of men and 61.4% of women experience moderate to high levels of chronic stress (p=0.002). Conclusion. The control of the main behavioral and biological risk factors of cardiovascular diseases development together with effective glycemic control are required to manage cardiovascular risk in persons with type 1 diabetes mellitus.
- 1 January 2026
- Published by Geotar-Media Publishing Group in Medical Education and Professional Development
- Vol. 17 (1)
Stratification of pharmacotherapeutic competencies: from deficit diagnosis to differentiated training
- 1 January 2026
- Published by Geotar-Media Publishing Group in Medical Education and Professional Development
- Vol. 17 (1)
Stratification of pharmacotherapeutic competencies: from deficit diagnosis to differentiated training